Related Experiment Video
Updated: Jul 18, 2026

The Adjuvant Efficacy of Angong Niuhuang Pill in the Treatment of Viral Encephalitis: A Meta-Analysis of Randomized Controlled Trials
Published on: April 19, 2024
Review of progressive multifocal leukoencephalopathy and natalizumab
1Mayo Clinic College of Medicine, Department of Neurology, Rochester, Minnesota 55905, USA. aksamit@mayo.edu
Background:
Progressive multifocal leukoencephalopathy (PML), a destructive demyelinating infection which lytically infects oligodendrocytes, has occurred in patients treated with natalizumab. Magnetic resonance imaging (MRI) scan imaging of the brain gives clues to diagnosis but is nonspecific in distinguishing multiple sclerosis from PML. Spinal fluid detection of JC virus is specific but incompletely sensitive. Associated immunosuppression is typically of the cell-mediated type but can be poorly defined on clinical grounds.
Review Summary:
It is apparent that natalizumab is a predisposing factor for developing PML from the 3 cases of natalizumab-treated patients. There is no reliable presymptomatic way to detect PML or JC virus infection of the brain by virologic or imaging surveillance techniques. One patient with multiple sclerosis and natalizumab treatment has survived, indicating that withdrawal of antibody, possibly in combination with antiviral therapy, may permit survival. However, immune reconstitution disease is a risk after immune restoration and withdrawal of natalizumab. PML deficits would be expected to be permanent. The estimate of incidence of PML in natalizumab-treated patients is 1 per 1000. The duration of natalizumab treatment may be an independent risk factor for development of PML.
Conclusion:
PML, a usually fatal neurologic infection, should be considered as a risk factor when using natalizumab. The treatment of multiple sclerosis patients with natalizumab is a matter of informed risk, individualized for each multiple sclerosis patient.
Insights
Progressive multifocal leukoencephalopathy (PML) is a risk for natalizumab users. Early detection of PML or JC virus is challenging, but natalizumab withdrawal may improve survival in multiple sclerosis patients.
Area of Science:
- Neurology
- Infectious Diseases
- Immunology
Background:
- Progressive multifocal leukoencephalopathy (PML) is a demyelinating infection affecting oligodendrocytes.
- PML has been observed in patients undergoing natalizumab treatment.
- Distinguishing PML from multiple sclerosis (MS) using MRI is difficult; JC virus detection in spinal fluid is specific but not always sensitive.
Purpose of the Study:
- To evaluate the risk of PML in patients treated with natalizumab.
- To identify potential methods for early detection and management of PML.
- To inform risk-benefit assessments for natalizumab therapy in MS patients.
Main Methods:
- Case review of natalizumab-treated patients.
- Analysis of diagnostic challenges including MRI and JC virus detection.
- Assessment of treatment outcomes and risk factors.
Main Results:
- Natalalizumab is a predisposing factor for PML, with an estimated incidence of 1 in 1000.
- No reliable presymptomatic surveillance methods for PML or JC virus infection exist.
- Duration of natalizumab treatment may be an independent risk factor.
- One patient survived after natalizumab withdrawal and potential antiviral therapy, though immune reconstitution disease is a risk.
Conclusions:
- PML is a significant risk associated with natalizumab use and should be considered.
- Treatment of MS with natalizumab involves informed, individualized risk assessment.
- PML deficits are likely permanent, emphasizing the need for careful patient selection and monitoring.
More Related Videos
10:50Visualizing Impairment of the Endothelial and Glial Barriers of the Neurovascular Unit during Experimental Autoimmune Encephalomyelitis In Vivo
Published on: March 26, 2019
10:19High-throughput Flow Cytometry Cell-based Assay to Detect Antibodies to N-Methyl-D-aspartate Receptor or Dopamine-2 Receptor in Human Serum
Published on: November 23, 2013
Related Concept Videos
Encephalitis ll: Pathophysiology
Encephalitis l: Introduction
Multiple Sclerosis l: Introduction
Cryptococcal Meningitis
Nephrotic Syndrome II : Assessment and Medical Management
Glaucoma: Overview